Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 2,408 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dysplasia Mild Clear all

Conditions: Mild Cognitive Impairment (MCI), Social Isolation
Interventions: AI-based conversational intervention; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 75 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Post Traumatic Headache
Interventions: OnabotulinumtoxinA; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Traumatic Brain Injury
Interventions: Individualized Scheduled Telephone Support (ISTS), Usual Care (UC); Behavioral · Other
Lead sponsor: INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium; Other
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Durham, North Carolina • Fort Bragg, North Carolina • Fort Lewis, Washington + 1 more

Conditions: Ulcerative Colitis (Disorder)
Interventions: Hydroxychloroquine, Mesalamine; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Alzheimer Disease
Interventions: Interleukin-2, Placebo; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 50 Years to 86 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mild Cognitive Impairment, Probable Alzheimer's Disease
Interventions: Modified Atkins Diet, NIA Diet for Seniors; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteoarthritis, Hip
Interventions: Synvisc-One (hylan G-F 20), Placebo; Device
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 35 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 45
States / cities: Burmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 41 more

Conditions: Open Angle Glaucoma
Interventions: Goniotomy, Trabecular Micro-Bypass Stent, Cataract Extraction; Procedure · Device
Lead sponsor: New World Medical, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: La Crosse, Wisconsin

Conditions: Mild Cognitive Impairment
Interventions: Tiempo Juntos Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 55 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mild Atopic Asthma
Interventions: BITS7201A, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Alzheimer's Disease
Interventions: caprylic triglyceride, long-chain triglyceride; Drug
Lead sponsor: Cerecin; Industry
Eligibility: 55 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
Interventions: es-citalopram, Memantine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 50 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: JINZHEN Granules for Oral Solution, Placebo; Drug
Lead sponsor: Lianyungang Kanion Group, Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Canyon Country, California • Hialeah Gardens, Florida • Miami, Florida + 7 more

Conditions: Alzheimer´s Disease
Interventions: Immune Globulin Intravenous (Human), 10% (IGIV, 10%); Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 51 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Mild Cognitive Impairment, Healthy Controls
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Brain Injuries, Head Injury
Interventions: Biomarker Testing using the Alinity Whole-blood TBI biomarker i-STAT; Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Mild Traumatic Brain Injury
Interventions: Diagnostic test; Device
Lead sponsor: Carey Balaban; Other
Eligibility: 18 Years to 50 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: San Diego, California • Miami, Florida • Pittsburgh, Pennsylvania

Conditions: Alzheimer's Disease, Dementia
Interventions: Drug: EVP-6124, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 44
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 41 more

Conditions: Traumatic Brain Injury
Interventions: Transcranial direct current stimulation, sham tDCS; Device
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hepatic Impairment
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Atopic Dermatitis
Interventions: Atopiclair Nonsteroidal Cream, Aquaphor Healing Ointment, EpiCeram; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 2 Years to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Alzheimer's Disease
Interventions: florbetapir F 18, Flortaucipir F18, Brain PET Scan; Drug · Procedure
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 20 Years and older
Enrollment: 383 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 27
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 20 more

Conditions: Huntington Disease
Interventions: Ethyl-EPA (Miraxion™); Drug
Lead sponsor: Amarin Neuroscience Ltd; Industry
Eligibility: 35 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 31 more

Conditions: Dry Eye Disease (DED)
Interventions: Systane Pro Topical Ophthalmic; Drug
Lead sponsor: Gordon Schanzlin New Vision; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

AI-CONECT: A Conversational AI for Early Dementia Prevention in Socially-Isolated Older Adults

Treatment of Chronic Post-Traumatic Headache With OnabotulinumtoxinA

CONcussion Treatment After Combat Trauma (CONTACT)

Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

Phase II Clinical Trial of Interleukin-2 in AD

Dietary Treatments for Cognitive Impairment in Older Adults

A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip

A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction

A Physical Activity Intervention to Promote Cognitive Health, Cardiovascular Health and Sleep in Older Latinos

A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma

AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)

Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment

JINZHEN for Treatment of Mild to Moderate COVID-19

Long-Term Study of IGIV, 10% in Alzheimer´s Disease

Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease

Biomarker Role in Assessing Imaging Needs for Mild Cranial Trauma

Standardized Instruments to Provide Diagnostic and Prognostic Information in Mild Traumatic Brain Injury (mTBI)

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

Treating Mild Traumatic Brain Injury With High Definition Transcranial Direct Current Stimulation

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

Effectiveness of Systane PRO for Mild to Moderate Dry Eye Disease